HOW NEMLUVIO WORKS FOR PRURIGO NODULARIS

Itch relief and skin healing from the inside out*

Not an actual patient.

NEMLUVIO® is the first and only treatment that blocks IL-31 signaling, a key driver of itch, inflammation, and the formation of prurigo nodularis (PN) nodules. By relieving itch and reducing the urge to scratch, NEMLUVIO allows your skin to heal.1

NEMLUVIO® is the first and only treatment that blocks IL-31 signaling, a key driver of itch, inflammation, and the formation of prurigo nodularis (PN) nodules. By relieving itch and reducing the urge to scratch, NEMLUVIO allows your skin to heal.1

Get the relief you’ve been waiting for with NEMLUVIO

Fast itch relief as soon 
as 48 hours2†

Itch relief that lasts 
so skin can heal2

Long-lasting 
skin clearance2

Fewer sleepless nights2‡

Favorable safety profile1

~Once-monthly dosing 
from the start1

Individual results may vary.

PP-NRS response defined as a ≥4-point improvement from baseline. Data from Phase 3 clinical study (OLYMPIA 2) post hoc descriptive analysis of daily PP-NRS improvement; consistent results seen in OLYMPIA 1. Significant improvement was achieved at 48 hours (15% vs 3% with placebo, P≤0.005).1,2

Who is NEMLUVIO for?

NEMLUVIO is intended for adults over the age of 18 who have been diagnosed with PN. If you are experiencing symptoms of PN, talk to a dermatologist about NEMLUVIO.1

Not an actual patient.

How does NEMLUVIO work?

Beneath the skin’s surface, in the sensory nerves, a key protein called IL-31 triggers signals to the brain that cause you to itch. Take a look at how NEMLUVIO blocks IL-31 signaling to help stop scratching, so you can start feeling relief.1,3


PN starts with signals beneath the skin
NEMLUVIO is designed to directly 
block IL-31 signaling

In PN, IL-31 is overactive and floods the 
nerves with signals for itch3

Image of the Prurigo Nodularis (PN) Itch Signal Pathway

Signals reach the brain and cause an 
intense urge to scratch3

Image of the Prurigo Nodularis (PN) Itch Signal Pathway

The skin becomes inflamed and breaks down, leading to the formation of nodules3,4

NEMLUVIO helps block IL-31 signaling for
itch and inflammation1

Image of the Nemluvio® Itch Signal Blocking Pathway

Blocking IL-31 signals helps stop the 
urge to scratch3

Image of the Nemluvio® Itch Signal Blocking Pathway

By reducing itch and inflammation, 
NEMLUVIO allows the skin to heal and clear1

swipe to see how
NEMLUVIO works
Image of the Prurigo Nodularis (PN) Itch Signal Pathway
Image of the Nemluvio® Itch Signal Blocking Pathway
 

Success with NEMLUVIO starts here

Understand what to expect throughout your experience with NEMLUVIO. Explore the guides, instructions for use, and other supportive resources.

VIEW Resources  

Not an actual patient.

Proven skin clearance that lasts1

Learn how adults using NEMLUVIO achieved clearer skin by Week 16 and beyond.1

Adults with PN reported sleeping better while on treatment with NEMLUVIO.2

IL-31=Interleukin 31; PP-NRS=Peak Pruritus Numerical Rating Scale; TCI=topical calcineurin inhibitor; TCS=topical corticosteroid.

References: 1. NEMLUVIO (nemolizumab-ilto) injection 30 mg Prescribing Information. Dallas, TX: Galderma Laboratories, L.P. 2. Galderma Laboratories, L.P.; data on file. 3. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. Expert Rev Clin Pharmacol. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080 4. Mullins TB, Sharma P, Riley C, Syed HA, Sonthalia S. Prurigo nodularis. In: StatPearls. StatPearls Publishing; March 1, 2024.

Important Safety Information

Indications: NEMLUVIO® (nemolizumab-ilto) is a prescription medicine used:

  • to treat adults and children 12 years of age and older with moderate-to-severe eczema (atopic dermatitis or AD) in combination with prescription therapies used on the skin (topical) when the eczema is not well controlled by topical therapies alone. It is not known if NEMLUVIO is safe and effective in children with atopic dermatitis under 12 years of age.
  • to treat adults with prurigo nodularis. It is not known if NEMLUVIO is safe and effective in children with prurigo nodularis under 18 years of age.

Do not take NEMLUVIO if you are allergic to nemolizumab-ilto or to any ingredients in NEMLUVIO. Before taking NEMLUVIO, tell your healthcare provider about all of your medical conditions, including if you:

  • are scheduled to receive any vaccination. You should not receive a live vaccine right before or during treatment with NEMLUVIO.
  • are pregnant or plan to become pregnant. It is not known whether NEMLUVIO will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known whether NEMLUVIO passes into your breast milk and if it can harm your baby.

Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

NEMLUVIO may cause serious side effects, including: allergic reactions (hypersensitivity). Stop using NEMLUVIO and tell your healthcare provider or get emergency help right away if you get any of the following symptoms:

  • Breathing problems or wheezing
  • Swelling of the face, lips, mouth, tongue, or throat
  • Fainting, dizziness, feeling lightheaded
  • Fast pulse
  • Swollen lymph nodes
  • Joint pain
  • Fever
  • Skin rash (red or rough skin)
  • Nausea or vomiting
  • General ill feeling
  • Cramps in your stomach area

The most common side effects of NEMLUVIO include:

  • Eczema: headache, joint pain, hives (itchy red rash or wheals), and muscle aches
  • Prurigo Nodularis: headache and skin rashes: atopic dermatitis (a type of eczema), eczema, and eczema nummular (scattered circular patches)

These are not all of the possible side effects of NEMLUVIO.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Patient Information.